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Abstract 
The clinical success of cisplatin continues to inspire the development of metal-based anti-cancer drug 
candidates. This article is meant to present the current state-of-the-art and science of ruthenium(II) and 
rhenium(I)-based anticancer drug candidates born out of our work in this field. Our recent efforts to 
elicit photoactivation of intact (organo)metallic anticancer drug candidates as a promising way for 
commanding their activity within cancer cells are also briefly summarised.  
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The clinical success of DNA-targeting classical Pt(II) chemotherapeutics underpins the tremendous 
potential of metal-based therapeutics in anti-cancer drug discovery.1-4 The Pt(II) anti-cancer agents 
however have continuously suffered from poor selectivity, severe side effects, and development of 
resistance.3-5 Thus, it is not surprising that other transition metal complexes have also been widely 
investigated as potential anti-cancer agents in a quest to develop new and improved anti-cancer drugs 
that can potentially overcome some of these obstacles on account of their novel mechanism of action. 
Importantly, a considerable attention is now being given to designing metallo-cytotoxics which target 
other sub-cellular components, where the cytotoxic action in cancer cells can be controlled and guided.2-
4,6  
In this article, we aim to highlight our recent contributions in this field. In particular, focus will be 
placed on the novel (organo)metallic complexes and their bioconjugates developed as potential 
cytotoxics, as well as on our efforts towards elucidation of their mechanism of action. In addition, in 
this article, we will also discuss some of the design strategies that have been employed in our 
laboratories to achieve a site-directed spatially and temporally controlled anti-cancer activity from such 
metallo-cytotoxics.  
 
Ruthenium(II) complexes 
Ruthenium compounds are the best examples to demonstrate the success with anti-cancer 
metallodrugs beyond platinum-based agents, with two of these – imidazolium trans-
[tetrachloro(dimethylsulfoxide)-(1H-imidazole)ruthenate(III) (NAMI-A) and indazolium trans-
[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) – in clinical trials.6 Despite their structural 
similarities, these two Ru complexes exert their cytotoxic action differently. The mechanistic hypothesis 
that the active species responsible for the anti-cancer properties of NAMI-A and KP1019 are 
Ru(II)-based has encouraged cytotoxicity studies on other Ru(II) compounds, including investigations 
carried out by us and others on substitutionally inert Ru(II)-tris(diimine) complexes.1-3,7-18  
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Ru(II)-tris(diimine) complexes have for long been investigated for their photophysical properties. 
Their absorption in the visible region of the electromagnetic spectrum, large Stokes shift, long lived 
metal to ligand charge transfer (MLCT) state, accessibility of the RuII/III electrochemistry, and a good 
thermal and chemical stability are features appropriate for their application as luminescent and 
electrochemical probes, and as fluorophores for cellular imaging applications.19-21 The rich Ru(II)-
polypyridyl chemistry also allows for fine tuning of the absorption and emission properties, playing a 
pivotal role in further growth in the application of ruthenium(II) compounds in biosensing, molecular 
and optical electronics, alternate energy and nanotechnology.18-21  
These complexes have also been of great interest for research groups, including ours, working in the 
field of medicinal and biological inorganic chemistry, particularly for cancer treatment. Pioneered by 
Dwyer, exploration of the biological activities of ruthenium polypyridyl complexes have revealed that, 
unlike platinum complexes, which target DNA and, thus, run the risk of serious side effects, interaction 
with DNA is not always essential for the activity of ruthenium(II)-tris(diimine) complexes.9,12-13,16-18,22 
Collectively, these results also demonstrate that subtle alterations in the lipophilicity, charge and 
structure of the ligand environment around the ruthenium(II) centre can direct such complexes to a wide 
range of sub-cellular molecular targets (e.g., the active site of an enzyme, mitochondria, endoplasmic 
reticulum, and the cellular membrane), resulting in a broad antiproliferative profile. Our particular 
interest has been in the cytotoxic behaviour of Ru(II) complexes containing dppz (dppz = dipyrido[3,2-
a:2′,3′-c]phenazine), the extended aromatic ligand.12-13,16-17 Polypyridyl Ru(II) complexes of dppz 
ligand are quite well known DNA intercalating "molecular-light switches", a characteristic feature that 
can be used for developing biosensors to probe the cellular microenvironments and the 
biomolecules.18,23-27  
In one such study, we investigated the cytotoxic effect of [Ru(dppz)2(CppH)](PF6)2 (1, Figure 1) (CppH 
= 2-(2′-pyridyl)pyrimidine-4-carboxylic acid) on a range of cancer lines (Table 1).17 As the cytotoxicity 
data shows, 1 induced an inhibitory effect similar to that of cisplatin, the Pt(II)-based anticancer drug 
routinely used for assessing the efficacy of anti-cancer action for novel drug candidates. More 
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importantly, when tested against the cisplatin-resistant cell line A2780-CP70, 1 showed a threefold 
improvement in cytotoxicity compared to cisplatin.17 Also, a lower toxic effect on the non-cancerous 
lung fibroblasts (MRC-5) was observed for 1 compared to cisplatin, the measurements being performed 
under identical experimental conditions. A comparison of the IC50 values of 1 with those of 2 and 3, 
related Ru(II) complexes of CppH ligand featuring bipyridyl units in place of dppz (Figure 1), was also 
made. Unlike 1, complexes 2 and 3 were found to be non-toxic across the cell lines tested.17 These 
results provided a strong evidence on the importance of dppz unit in the cytotoxicity observed for 1.  
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Figure 1. Structures of bis(dppz)-Ru(II) derivatives (racemic mxtures) investigated as anti-cancer agents.12,17 
Table 1. Cytotoxic activity data (IC50) for 1, cisplatin and dequalinium chloride hydrate against human cancer 
and non-cancerous lung fibroblast (MRC-5) cell lines.17 
IC50 (µM) 
 HeLa MCF7 U2OS A2780 A2780-CP70 MRC-5 
1 10.0 ± 1.3  4.3 ± 0.1 13.5 ± 2.5 2.8 ± 0.1  4.0 ± 1.2  15.1 ± 2.2  
Cisplatin 11.5 ± 2.9  1.8 ± 0.3  11.8 ± 1.7 2.9 ± 0.6 13.8 ± 3.0 7.9 ± 1.2 
Dequalinium 
chloride hydrate 
21.9 ± 3.6 2.9 ± 0.5 13.4 ± 2.5 1.0 ± 0.1 1.7 ± 0.7 48.9 ± 7.6 
The cell viability was determined by using the resazurin reduction test, after treatment with the test compound for 48 h. 
 
 
We conducted subsequent in vitro studies to establish the mode of cytotoxic action for 1. As a first step 
towards this, we investigated the intercellular localization of 1 in cervical cancer (HeLa) cells. The 
inherent MLCT luminescence of 1 was used to probe the cellular localization using confocal laser 
scanning microscopy (CLSM) (Figure 2).17 In HeLa cells, 1 displayed a luminescence signal mainly 
from the cytoplasm with only weak detectable emission observed from the cell nucleus. To determine 
the exact localization of 1 within the cytoplasmic organelles comprehensive colocalization experiments 
with Mitotracker green FM, a mitochondrial stain, were also performed. An excellent superimposition 
between the luminescence signal from the commercially available dye and 1 established mitochondria to 
be its primary target inside the cells (Figure 2(d)).17 To further confirm this, cellular and mitochondrial 
uptake of 1 was quantified by high-resolution continuum source atomic absorption spectrometry (HR-
CS AAS). This is an extremely useful technique for quantitative determination of the metal 
concentrations in cellular organelles.28 Being in line with our earlier observations from confocal 
microscopy studies, the mitochondrial ruthenium content determined by HR-CS AAS of 1 was 68% of 
its total uptake in HeLa cells.17  
In subsequent studies we investigated the mechanism for cell uptake and cytotoxicity using flow 
cytometry, YO-PRO, annexin-V and Caspase-Glo 3/7 assays.17 These studies revealed the uptake of 1 
in HeLa cells to be energy dependent, and that 1 induces cell death by apoptosis, albeit in a relatively 
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gradual manner compared to cisplatin. In addition it was noticed that 1 is capable of impairing the 
mitochondrial membrane potential in HeLa cells as early as 2 h after treatment. On the basis of 
appropriate control experiments using N-acetylcysteine, a reactive oxygen species (ROS) scavenger, 
any potential production of ROS and its contribution to the observed cytotoxicity of 1 was ruled out.  
Furthermore, by means of human plasma stability studies, the cytotoxic action of 1 was ascribed to its 
intact form since the compound was found to not decompose.17 This observation is of particular 
relevance here as it indicates the robustness of such Ru(II)-polypyridyl frameworks in biological media.  
 
Figure 2. Fluorescence confocal microscopy images of HeLa cells incubated with 1 (20 μM) for 2 h and 
Mitotracker green FM for 45 min: (a) DAPI staining; (b) cellular staining of 1; (c) Mitotracker green FM staining; 
and (d) the overlay image. Reproduced with permission from ref. 17 © 2012 American Chemical Society. 
Following on from above, in the next phase of the studies, we investigated the cytotoxic action of 4–
17, fourteen structural analogues and organelle/receptor-targeting peptide bioconjugates of 1 (Figure 
1).12 These studies were anticipated to assist in inducing selectivity and control in the mitochondria-
mediated apoptosis of 1. It is important to note that such structure-activity correlation studies are much 
needed for understanding the influence of the individual ligands and functional groups in the 
cytotoxicity derived from metal complexes that may serve as a basis for designing metal-based anti-
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cancer drug candidates with improved activity. Interestingly, and somewhat surprisingly, complex 1 
was found to be more active than all the fourteen analogues screened, with structural and functional 
modifications of the CppH ligand resulting in at least a fourfold decrease in activity.12 
A particularly important finding to emerge from the these studies was that the activity of 1 is 
controlled by the existence of a free carboxylic acid functionality of the CppH ligand and the bis(dppz) 
framework around the Ru(II) centre. This led to the idea of covalently introducing a photocleavable 
moiety, 3-(4,5-Dimethoxy-2-nitrophenyl)-2-butyl (DMPNB) ester on the carboxylic group in an attempt 
to improve the selectivity of 1.13 The light-activatable pro-moiety 18 (Figure 3) synthesised this way is 
the first example of a coordinatively-inert metal complex-based prodrug system which can efficiently 
respond to activation by light to display cytotoxicity "on demand" against cervical (HeLa) and bone 
cancer (U2OS) cells.13 The cytotoxicity evaluations done on 18 showed it to be non-toxic in the dark 
(even after the cell were exposed for an extended period of 48 h), whilst re-attaining similar cytotoxic 
levels as of the photocaged drug candidate 1 upon giving quite low doses (2.58 J cm-2) of light 
irradiation to cells at 350 nm (Table 2).13  The light-triggered liberation of 1, from the prodrug candidate 
18, thus allows for an effective modulation of its cytotoxic action in cancer cells.  
 
Figure 3. Chemical structures of the DMPNB photocaged bis(dppz)-Ru(II) complex 18 (isolated as racemic 
mixtures of hexafluorophosphate salts). The active compound 1 is released upon irradiation at 350 nm.13 
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In another noteworthy study, we examined the anti-cancer activity of 19–24, six substitutionally inert 
Ru(II) complexes bearing different functional groups on the dppz ligand (Figure 4).16 In particular, we 
explored their prospects as photosensitizers (PS) in photodynamic therapy (PDT). Known to be classical 
DNA intercalators, such Ru(II) polypyridyl complexes can be effective photosensitized anti-cancer 
agents because of their promising singlet oxygen generation feature, and capability to cleave DNA upon 
photoirradiation.22,29-32 Our objective was to present an excellent starting point for assessing more such 
Ru(II)-dppz complexes as PSs in PDT.31-32  
 
Figure 4. Series of [Ru(bpy)2(dppz-R)]2+ derivatives investigated as photocytotoxics.16  
Table 2. Photocytotoxic activity data (IC50) for 18–24, and cisplatin against human cervical carcinoma 
(HeLa), human osteosarcoma (U2OS) and non-cancerous lung fibroblast (MRC-5) cell lines.13,16 
IC50 (µM)
HeLa U2OS MRC-5 
4 h (+ light)a 48 h (dark) 4 h (+ light) 48 h (dark) 48 h (dark) 
18 17.0 ± 0.8 (350 nm) 85.8 ± 5.8 17.2 ± 3.8 (350 nm) > 100 85.3 ± 0.2  
19 25.1 ± 7.6 (350 nm)     
2.0 ± 0.9 (420 nm)   > 300 n.d n.d > 100 
20 9.0 ± 1.4 (350 nm)      
5.5 ± 0.7 (420 nm)   235.5 ± 24.7 n.d n.d > 100 
21 > 100 (350 nm)         
> 100 (420 nm) > 100 n.d n.d > 100 
22 > 100 (350 nm)         
20.8 ± 1.0 (420 nm)   > 100 n.d n.d > 100 
23 > 100 (350 nm)         
> 100 (420 nm) > 100 n.d n.d > 100 
24 47.5 ± 9.4 (350 nm)   
20.5 ± 4.4 (420 nm)   > 100 n.d n.d > 100 
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Cisplatin 26.8 ± 1.7 (350 nm)   
26.8 ± 2.4 (420 nm)   9.9 ± 0.9  32.6 ± 5.1 11.8 ± 1.7 8.5 ± 0.9 
a 10 min 350 nm irradiation (2.58 J cm-2) or 20 min 420 nm irradiation (9.27 J cm-2). n.d = not determined.  
  
As anticipated, in acetonitrile, all the Ru(II) complexes displayed high efficiencies for singlet oxygen 
generation when photoirradiated with a 350 nm or 420 nm light. The results were in accord with our 
findings from the DFT calculations, which showed the lowest-lying triplet state to have a 3π-π* 
character allowing the photogenerated PS excited state molecules to react with molecular oxygen (3O2) 
and give rise to singlet oxygen (1O2).16 We followed these findings with evaluating the cytotoxic effects 
of 19–24 on HeLa and MRC-5 cell lines (Table 2). The experiments were conducted on cells kept in the 
dark and after exposing them to irradiation with 350 nm (2.58 J cm-2) or 420 nm (9.27 J cm-2) light. In 
the dark, all the Ru(II)-ddpz variants were found to be non-toxic to the cells on incubation for up to 48 
h. Upon photoirradiation, complexes 19 and 20 showed a remarkable increase in their toxicity. In 
particular, 420 nm light activation elicited more than 150-fold enhancement over the dark toxicity in the 
case of 19, the dppz-NH2 variant.16 
We subsequently studied the uptake and localization of complexes 19 and 20 in HeLa cells.16 On the 
basis of confocal microscopy studies, it appeared that 20 mainly accumulates in the cell nucleus. In case 
of 19, however, only a weak luminescence was observed making it difficult to make any interpretation 
on its cellular localisation (Figure 5). The low luminescence signal observed for 19 inside the cells is 
not completely surprising, as a large number of the Ru(II)-dppz complexes can also exhibit solvent 
polarity-dependence of luminescence intensities. However, for 19 this was postulated to be mainly due 
to its poor quantum yield for emission (Φem = 0.1 in acetonitrile).16  
Cellular localization of the Ru(II)-dppz complexes cannot always be claimed on the basis of the 
intensity of luminescence signal observed from confocal microscopy.18,25-27 Undoubtedly there are 
systems such as 1 where this is indeed the case, however, it should be noted that in some cases the 
observed intensities may be reflecting enhanced localization in hydrophilic or hydrophobic cellular 
microenvironment, rather than an actual uptake in various cellular compartments. We employed HR-CS 
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AAS to quantify the uptake of 19 and 20 in HeLa cells. This analysis confirmed high uptake of 19 and 
20 into the cells (1.08 mmol and 1.76 mmol Ru per mg protein, respectively), as well as their nuclear 
uptake in concentrations sufficient enough to assign their phototoxicity to nuclear mode of action. 
Subsequent DNA photocleavage studies were performed on supercoiled pcDNA3 plasmid which 
confirmed 19 and 20 to induce efficient DNA cleavage in response to 420 nm light activation, results in 
parallel with the in vitro phototoxicity measured in HeLa cells.16 Of note, lately, we have succeeded in 
taking our research on PDT applications for Ru(II) complexes a step further by developing Ru(II) 
polypydriyl complexes that can be used as potential PSs for PDT as well as antimicrobial photodynamic 
therapy (aPDT) applications.33 
 
Figure 5. Confocal microscopy localization experiments on HeLa cells treated for 2 h with 100 μM of complex 
20 (excitation at 488 nm, emission above 600 nm, bottom left) and stained with DAPI (nuclear staining, top left) 
and with Mitotracker green (mitochondrial staining middle left); in the yellow circle a representative example of 
the different localization of 20 and Mitotracker green (picture on the right). Reproduced with permission from ref. 
16 © 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
Rhenium(I) complexes 
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Another family of metal complexes that have attracted our research interest are the luminescent 
bis(quinolinoyl) Re(I) tricarbonyl complexes. Rhenium(I) organometallic compounds have been far less 
explored compared to other organometallic complexes as anti-cancer drug candidates.6,34 One of the 
advantages of bis(quinolinoyl) Re(I) tricarbonyl complexes is that they do not require any external 
fluorophore for being traced inside cells using confocal imaging.19,21,35-36 This can be a very useful 
feature for any cytotoxic metal complex to have since it offers an easy way to monitor its intracellular 
distribution.25,36 Furthermore, compared to other classes of Re(I) compounds, the bis(quinolinyl) Re(I) 
tricarbonyl complexes offer a much simpler and direct way of fine tuning chemical structure, thereby 
offering potential access to a large library of such complexes for investigation as anti-cancer agents.   
We investigated in detail the cytotoxicity and mechanism of anti-cancer action of a Re(CO)3 complex, 
25 (Figure 6),37 which was previously used as a “clickable” luminescent complex.38-39 Complex 25 was 
found to induce toxicity in the micromolar range when tested against the human osteosarcoma (U2OS), 
human hepatocellular liver (HepG2), and human breast (MCF-7) carcinoma cell lines (IC50 = 16.4 μM, 
25.5 μM and 6.1 μM, respectively). Interestingly, our efforts to locate the complex inside the living cells 
using fluorescence microscopy were unsuccessful. Contrary to our initial anticipation, the absence of 
luminescence signal was observed for 25 despite the complex itself possessing luminescent 
characteristics in-solution. Explanation for this unusual observation was provided by the DFT studies 
and photophysical characterisation of 25, which involved recording the emission spectra for 25 at 
different concentrations and in solvents of different polarities, in the presence and absence of oxygen.37 
A dependence of emission on the polarity of the solvent as well the concentration of the complex was 
noted. Also, the emission showed sensitivity to dissolved oxygen in all solvents. In combination, these 
findings provide insight into the lack of any emission in living cells for 25. However, there still remain 
several open questions about this unusual photophysical behaviour of 25 in living cells.  
We then investigated in detail the potential mode of action for 25.37 In T lymphocyte Jurkat cells, it 
was found to induce a concentration-dependent ROS production, leading to apoptosis. Influence on cell 
metabolism was studied in real time on MCF-7 cells, employing a biosensor chip system. Spontaneous 
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decrease in cellular respiration along with increased glycolysis was observed. Subsequent studies on 
isolated mitochondria confirmed this to be an obvious outcome of the inhibition of mitochondrial 
activity. At its low concentrations (5–10 μM), 25 was found to increase oxygen consumption, rapidly 
blocking respiration at 40 μM complex concentration.37  
In a follow-up study, we also investigated the cytotoxic behaviour of the amino and carboxylate 
functionalised bis(quinolinoyl) Re(I) tricarbonyl complexes, 26 and 27, respectively (Figure 6).40 In 
addition to the free complexes, we also studied their respective organelle/receptor-targeting peptide 
bioconjugates 28  and 29 (Figure 6),40 designed with an intention to develop systems with selectivity 
and efficacy in anti-cancer action. Prior to assessing their cytotoxic potential, 26 and 27 were assessed 
for their ability to generate singlet oxygen upon light irradiation. There are sufficient examples of Re(I) 
complexes in literature possessing reasonable 1O2 photogeneration profile.31 Our Re(I) tricarbonyl 
complexes were also found to be promising 1O2 generators exhibiting quantum yields of ca. 20% and 
75% in water and acetonitrile, respectively, upon irradiation with 350 nm light.40  
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Figure 6. Chemical structures of Re(I)(CO)3 derivatives investigated as anti-cancer agents.37,40-41  
In subsequent studies, we investigated the localization of 26–29 in HeLa cells. On the basis of 
observed emission signals, the Re(I) complexes 26 and 27 appeared to accumulate specifically in the 
cytoplasm and distribute homogeneously throughout the cell, respectively.40 Whilst the nuclear 
localised signal (NLS)-conjugated 28 showed enhanced uptake in the cell nucleoli, no definitive 
conclusions could be derived on the exact intra-cellular location of the Re(I)-bombesin conjugate, 29, as 
it showed a much lower emission. When assessed for their cytotoxic effect on HeLa and MRC-5 cell 
lines (Table 3),40 4 h after administration, the Re(I) complexes 26 and 27 showed no inhibitory effect 
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with IC50 values not reached up to the tested concentrations of 100 μM, in the absence of any light 
irradiation. Relative to 27, whilst the NLS-conjugated Re(I) complex 28 showed enhanced toxicity 
towards both HeLa and MRC-5 cells (IC50 = 35.1 μM and 18.3 μM, respectively), the bombesin 
conjugation for 29 resulted in a moderate toxic response being noted on MRC-5 cells (IC50 = 44.1 μM). 
Interestingly, all the test compounds showed significant improvement in toxicity (IC50 = 5.3–18.3 μM) 
toward HeLa cells with light irradiation at 350 nm (2.58 J cm-2) highlighting the potential of such Re(I) 
tricarbonyl complexes to be developed as efficient photosensitizers.40 DNA photocleavage experiments 
later conducted on the pcDNA3 plasmid confirmed 1O2 induced photodamage of DNA, further 
reflecting on the photodynamic activity of complexes 26–29.40   
Table 3. Cytotoxic activity data (IC50) for Re(I) derivatives 26–31, and cisplatin against human cervical 
carcinoma (HeLa), prostate carcinoma (PC-3) and non-cancerous lung fibroblast (MRC-5) cell lines.40-41 
IC50 (µM) 
HeLa PC-3 MRC-5 
4 h (+ UV-A)a 48 h (dark) 4 h (+ UV-A)a 48 h (dark) 4 h (+ UV-A)a 48 h (dark) 
26 17.3 ± 2.9  187.1 ± 17.9 > 100 > 100 40.3 ± 5.4  > 100 
27 9.3 ± 2.2   > 100 n.d n.d n.d > 100 
28 18.3 ± 1.4  35.1 ± 1.8 n.d n.d 13.0 ± 2.5 17.8 ± 1.8 
29 5.3 ± 1.0  > 100 13.6 ± 1.7  > 100 41.6 ± 15.9 44.1 ± 9.9 
30  9.3 ± 0.8   14.5 ± 5.2  n.d n.d 20.5 ± 5.5 36.2 ± 0.6 
31  9.7 ± 4.4   > 100 19.2 ± 2.4  > 100 23.3 ± 0.6 72.3 ± 3.6 
Cisplatin 26.8 ± 1.7    9.2 ± 0.6  74.8 ± 14.8 15.7 ± 3.5 47.8 ± 1.5 10.5 ± 2.8 
a 10 min UV-A irradiation (350 nm, 2.58 J cm-2). n.d = not determined. 
 
Building upon these findings, in our recent research on such cytotoxic Re(I) tricarbonyl complexes, 
we have also attempted to take advantage of light as external trigger to control their activity inside cells. 
Compounds 30 and 31 (Figure 6), the photolabile protecting group (PLPG) containing variants of 28 
and 29, were studied for their photoinduced toxicity along with an in-depth biological characterization 
of 30.41 The effect of light irradiation on the cytotoxic action of 30 and 31 was studied on HeLa and 
MRC-5 cells, with 31 further examined for inhibitory effect on prostate cancer (PC-3) cells (see Table 3 
for IC50 values).41 In the dark, 30 showed low-micromolar range of toxicity on HeLa and MRC-5 cells. 
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On the other hand, 31 showed moderate toxicity towards MRC-5 cells, but did not induce any 
cytotoxicity towards HeLa and PC-3 cells in the dark, even after 48 h of treatment with 100 μM 
complex concentration.  
 
Figure 7. Fluorescence confocal microscopy images of HeLa cells incubated with Re-NH2 (26) and Re-PLPG-
NLS (30) (50 µM, 1h). Untreated and Re-PLPG treated cells were used as controls. Adapted with permission 
from ref. 41 © 2014 Royal Society of Chemistry. 
With light irradiation at 350 nm (2.58 J cm-2), an improvement in cytotoxicity was seen for both the 
complexes.41 The inclusion of PLPG group in 30 resulted in an improvement in the phototoxicity profile 
compared to 28, making it more active toward the cancerous (HeLa) cells, also decreasing its effect on 
noncancerous (MRC-5) cells. As judged by the staining patterns obtained from confocal microscopy 
experiments on HeLa cells, 30 appeared to mainly accumulate in the nucleoli (Figure 7). We 
substantiated these findings by the ICP-MS measurements, which revealed an efficient uptake of 30 in 
the cells with more than 25% being delivered to the nucleoli. Subsequently, we studied the 
 17
morphological alterations in HeLa cells exposed to 30 in the dark and after being subjected to light 
exposure. Representative transmission electron microscopy (TEM) images presented in Figure 8 
suggested 30 to trigger cell death by a combination of apoptosis and necrosis.41  
  
 
Figure 8. Transmission electron microcopy images of HeLa cells treated with 20 μM Re-PLPG-NLS (30) for 
2 h, showing death morphology in cells after irradiation at 350 nm (2.58 J cm-2); features detected were organelle 
packaging as well as cytoplasm condensation and pyknosis (yellow arrows), extensive vacuolation (blue arrows), 
shrinkage and membrane blebbing (green arrows), and nectrotic profile (red arrows). Adapted with permission 
from ref. 41 © 2014 Royal Society of Chemistry. 
 
Concluding Remarks 
To conclude, in the context of anti-cancer metallodrug candidates, we have showcased the great 
potential of coordinatively inert Ru(II) polyyridyl complexes and luminescent bis(quinolinoyl) Re(I) 
tricarbonyl complexes. These metal complexes can not only display cytotoxicity on their own, in the 
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dark, but also via photgeneration of toxic singlet oxygen. By way of examples, we have shown that 
tris(diimine) Ru(II) complexes and Re(I) carbonyl complexes, if identified as efficient singlet oxygen 
generators can be developed as effective PSs for PDT applications. We are now at a stage where some 
of these systems exhibit reasonable light-triggered anti-cancer activities. Their application is however 
limited by the fact that they require UV-A light to proceed. Future designs will need to yield systems 
which can be sufficiently reactive in physiologically most transparent optical window, obviating the 
need for UV radiations for light-triggered applications. In the short term, substantial gains in reactivity 
could be achieved by simply integrating the best aspects of existing designs into a single system. 
Beyond this, future efforts to develop improved metallocytotxics should also focus on metal complexes 
that can induce cancer cell death by multiple metal-based mode of actions, with greater selectivity, and 
have a high degree of cooperativity between these effects. Efforts are underway in our laboratories to 
thoroughly study a library of such complexes from photophysical, photochemical, thermodynamic and 
biological perspective, in order to concede novel metal-based anti-cancer drug candidates.  
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